Gelonghui July 10th | *ST Longjin (002750.SZ) announced its semi-annual performance forecast for 2024, reporting a net loss attributable to shareholders of the listed company of 3.6 million yuan to 4.9 million yuan, compared to a loss of 15.7777 million yuan in the same period last year; the net loss after deducting non-recurring gains and losses is 9.7 million yuan to 13.15 million yuan, compared to a loss of 19.4725 million yuan in the same period last year; the basic earnings per share is a loss of 0.0090 yuan/share to 0.0122 yuan/share.

Due to continuous impacts from policy factors such as medical insurance payment restrictions, hospital prescription limits, and the company's participation in the provincial alliance centralized volume procurement of traditional Chinese medicine with a 67% price reduction for injectable Dendrobium, as well as the gradual implementation of the volume procurement price linkage policy in non-procurement provinces, the company's operating income for the period has decreased.

During the reporting period, the company implemented measures to reduce costs and increase efficiency, improve capacity utilization, reduce production costs, and manage sales and administrative expenses with precision; at the same time, research and development projects gradually entered the capitalization stage, R&D expenses decreased, and the company received performance compensation from the committing party, which collectively led to a reduction in the loss amount compared to the same period last year.